Study Protocol for ‘PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity’

This study's results are expected to offer critical insights into the neural mechanisms underlying the effects of psilocybin-assisted therapy in treating OCD, and whether these correlate with changes in the cognitive features of the condition. As a secondary aim, it will ascertain whether a low, tolerable dose is a feasible and efficacious clinical treatment, and will provide crucial data to guide the design of a potential follow-up randomised control trial (RCT).

Authors

Institutions

Publication Details

Journal
Cureus
Published
2025-01-29
DOI
https://doi.org/10.7759/cureus.78171
Citations
2
Primary Topic
Psychedelics and Drug Studies
Type
article
Field-Weighted Citation Impact
4.61
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Study Protocol for ‘PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity’

Pedro Castro-Rodrigues, Martina Chiera, Ana Frota Lisboa Pereira de Souza, Dea Siggaard Stenbæk et al.
2 citations
Cureus
Psychedelics and Drug Studies
4.61
article

Study Protocol for ‘PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity’

Pedro Castro-Rodrigues, Martina Chiera, Ana Frota Lisboa Pereira de Souza, Dea Siggaard Stenbæk, Mairead Healy, Jonny Martell, Robin Lester Carhart-Harris, David Erritzøe, Naomi Fineberg, Kate Godfrey, Luca Pellegrini, Sean O’Connor, Trevor William Robbins, Joseph Peill, David Nutt, Hakjun Lee, Cyrus Rohani-Shukla, Robin J. Tyacke, Sara Reed, Maria Papasyrou
article en
2 citations

Abstract

This study's results are expected to offer critical insights into the neural mechanisms underlying the effects of psilocybin-assisted therapy in treating OCD, and whether these correlate with changes in the cognitive features of the condition. As a secondary aim, it will ascertain whether a low, tolerable dose is a feasible and efficacious clinical treatment, and will provide crucial data to guide the design of a potential follow-up randomised control trial (RCT).

CureusVol. 17(1)
Champalimaud Foundation (PT), University of Copenhagen (DK), University of Hertfordshire (GB), University of Trieste (IT), University of California, San Francisco (US), University of Cambridge (GB), Hertfordshire Partnership University NHS Foundation Trust (GB), Cambridge School (PT), Bridge University (SS), Azienda Sanitaria Universitaria Integrata di Trieste (IT), Imperial College London (GB), IT University of Copenhagen (DK), University of Bologna (IT)
Openalex Percentile: Top 8%
Psychedelics and Drug Studies
4.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.